Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and (Q73368715)
Jump to navigation
Jump to search
scientific article published on 01 May 1997
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and |
scientific article published on 01 May 1997 |
Statements
Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group (English)
P Postmus
A Ardizzoni
H Hansen
P Dombernowsky
T Gamucci
S Kaplan
B Schaefer
J Wanders